EZRA Reliance Global Group, Inc.
Price Chart
Executive Summary
Reliance Global Group (EZRA) formed LifeSci Global Group (51% owned) to invest $2M in Innervate Radiopharmaceuticals, a pre-revenue biotech developing a PET imaging agent for neuroblastoma. The investment is funded via a promissory note from EZRA's subsidiary and involves related-party interests from CEO and a board member. The deal offers potential upside from a Priority Review Voucher and large addressable markets, but carries high risk given Innervate's early stage, no revenue, and the substantial relative size of the investment (50% of EZRA's market cap).
Key Financial Metrics
Actionable Insight
Monitor Innervate's regulatory milestones (Phase III trial, NDA submission) and any PRV award, as these are key catalysts. The related-party structure and staged payments suggest careful governance scrutiny. EZRA's core insurance business fundamentals are not addressed here; watch for any impact on liquidity from further capital commitments.
Key Facts
- EZRA formed LifeSci Global Group (LGG) and owns 51% of membership interests; the remaining 49% is held by insiders (CEO, board member, associate).
- LGG subscribed for 421,053 Class A units of Innervate at $4.75/unit, total $2,000,001.75, payable $500K upfront and $150K/month for 10 months.
- LGG receives warrants for up to 210,526 additional units at $4.75 strike, expiring October 2029, and a priority distribution of $4.75/unit from PRV sale or liquidity event.
- EZRA's subsidiary EIG issued a $2M promissory note to LGG at 7% interest, maturing April 2031, with $500K already advanced.
- Innervate's lead asset (18F-mFBG) is in late-stage development for neuroblastoma; estimated neuroblastoma market opportunity ~$250M, with potential billion-dollar markets in cardiovascular and neurodegenerative diseases.
- The transaction was approved by independent directors; interested parties (CEO Beyman, director Korman) recused themselves.
- EZRA's market cap is ~$4M, making this a 50% of market cap investment in a pre-revenue biotech.
Financial Impact
Up to $2,000,001.75 investment in Innervate, with $500,000 funded at closing; potential for priority distribution of $4.75/unit ($2M) from future PRV sale or liquidity event.
Risk Factors
- Innervate has no prior operating history, no revenue, and needs substantial additional capital; product may never receive FDA approval.
- Related-party transaction with potential conflicts of interest (CEO and board member have interests on both sides).
- Investment is large relative to EZRA's market cap ($4M); any write-down would materially impact financials.
- Warrant issuance could cause future dilution to LGG's stake if exercised.
- License agreement with Ground Fluor Pharmaceuticals has milestone risks; termination could halt operations.
Market Snapshot
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-021123 |
| Exhibit: ex10-1.htm | 0001493152-26-021123 |
| Exhibit: ex99-1.htm | 0001493152-26-021123 |
| Exhibit: ex10-3.htm | 0001493152-26-021123 |
| Document: form8-k.htm | 0001493152-26-021123 |
| Document: 0001493152-26-021123-index-headers.html | 0001493152-26-021123 |
| Document: 0001493152-26-021123-index.html | 0001493152-26-021123 |
| Document: 0001493152-26-021123.txt | 0001493152-26-021123 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
6d ago
|
8-K
| $3.71 $3.75 | ▲ +1.08% | ▲ +0.68% | $3.63 (−2.16%) |
|
May 14, 2026
26d ago
|
Press Release
| $4.56 $4.84 | ▼ −6.14% | ▼ −7.37% | $3.63 (+20.39%) |
|
May 6, 2026
4w ago
|
Press Release
| $7.04 $7.00 | ▼ −0.57% | ▼ −0.24% | $3.63 (−48.44%) |
|
May 4, 2026
5w ago
|
8-K
| $6.80 $7.04 | ▲ +3.53% | ▲ +2.14% | $3.63 (−46.62%) |
|
Mar 24, 2026
11w ago
|
Insider Cluster
| $7.80 $6.80 | ▼ −12.82% | ▼ −13.39% | $3.63 (−53.46%) |
|
Mar 19, 2026
11w ago
|
Press Release
| $6.96 $7.28 | ▲ +4.60% | ▲ +6.34% | $3.63 (−47.84%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $8.40 $8.60 | ▲ +2.38% | ▲ +3.87% | $3.63 (−56.79%) |
|
Feb 25, 2026
14w ago
|
8-K
| $12.52 $12.08 | ▼ −3.51% | ▼ −2.97% | $3.63 (−71.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access